Patents Assigned to Merck
  • LIQUID-CRYSTAL MEDIUM
    Publication number: 20190241808
    Abstract: The present invention relates to a liquid crystal (LC) medium comprising polymerisable compounds, to a process for its preparation, to its use for optical, electro-optical and electronic purposes, in particular in LC displays, and to LC displays comprising it.
    Type: Application
    Filed: October 16, 2017
    Publication date: August 8, 2019
    Applicant: Merck Patent GmbH
    Inventors: Nils GREINERT, Matthias BREMER, Patrick SUESS, Christian SCHOENEFELD, Jochen SIEBERLING, Renate SEEGER, Anna Lisa HAWLITSCHEK
  • COMPOUNDS FOR THE HOMEOTROPIC ALIGNMENT OF LIQUID-CRYSTALLINE MEDIA
    Publication number: 20190241809
    Abstract: Liquid-crystalline media (LC media) comprising self-aligning mesogens (self-alignment additives) which effect homeotropic (vertical) alignment of the LC media at a surface or the cell walls of a liquid-crystal display (LC display). The self-alignment additives contain five-ring systems. LC displays having homeotropic alignment of the liquid-crystalline medium (LC medium) without conventional alignment layers are provided.
    Type: Application
    Filed: February 5, 2019
    Publication date: August 8, 2019
    Applicant: Merck Patent GmbH
    Inventors: Melanie KLASEN-MEMMER, Edward PLUMMER, Rocco FORTTE, Helmut HAENSEL, Timo UEBEL, Tamara LEHMANN
  • LIQUID CRYSTALLINE MEDIUM
    Publication number: 20190241811
    Abstract: The present invention relates to liquid crystalline media comprising one or more naphthothiadiazol derivatives of formula I, in which R11, R12, A11, A12, A21, A22, Z11, Z12, Z21, Z22, W, X11, X12, L, r, s and t have the meanings indicated in claim 1, to the use of such liquid crystal media for optical, electro-optical and electronic purposes, in particular in devices for regulating the passage of energy from an outside space into an inside space, for example in windows.
    Type: Application
    Filed: June 26, 2017
    Publication date: August 8, 2019
    Applicant: Merck Patent GmbH
    Inventors: Peer KIRSCH, Rene LUTZ, Michael JUNGE, Ursula PATWAL
  • ILT3 LIGAND
    Publication number: 20190241655
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind ILT3, ILT3 ligand (i.e., PI16) or a complex between ILT3 and the ILT3 ligand. Methods for determining whether ILT3 and the ILT3 ligand bind together or whether a substance agonizes or antagonizes such binding are also provided.
    Type: Application
    Filed: November 6, 2017
    Publication date: August 8, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Daniel Cua, Holly Cherwinski, Adele Wang, Yi Chen, Barbara Joyce-Shaikh
  • COLORING OF WAFERS AND SIMILAR BAKED GOODS
    Publication number: 20190239544
    Abstract: The present invention relates to the use of one or more pearlescent pigments based on flake-form substrates for coloring wafers, edible paper and similar baked goods.
    Type: Application
    Filed: February 7, 2018
    Publication date: August 8, 2019
    Applicant: MERCK PATENT GMBH
    Inventor: Ralf SCHWEINFURTH
  • Thermostable respiratory synctial virus (RSV) vaccine compositions
    Patent number: 10369213
    Abstract: Methods for improving the drying yield and stability of RSV vaccines comprising a highly thermolabile enveloped live virus and/or one or more RSV protein subunits, are described. Methods for rapid drying of RSV formulations containing between 17.5% and 60% w/w of a non-polymeric sugar and using either conduction or radiation dominant drying mechanisms, are disclosed. The disclosed methods provide for; 1) a dried RSV formulation with improved stability profile; 2) faster drying; and 3) integration of dried RSV into a primary device (such as dual chamber cartridges, foil-pouch devices etc.), pre- as well as post-drying.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: August 6, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Akhilesh Bhambhani, Robert K. Evans, Lynne A. Isopi
  • Micro-titration vessel
    Patent number: 10369571
    Abstract: A micro-titration vessel may include a plurality of fins protruding outward from an exterior wall of a cup and flush with the bottom of the cup to provide stability to the vessel. Interior walls of the cup are angled inward at multiple points along the body of the cup, resulting in a small surface area at the bottom of the cup where titration occurs.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: August 6, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventor: Tinh Nguyen-DeMary
  • Phenyl-cyanoquinolinone PDE9 inhibitors
    Patent number: 10370336
    Abstract: The present invention is directed to phenylcyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: August 6, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Victoria Cofre, Antonella Converso, Kevin Rodzinak
  • Materials for electronic devices
    Patent number: 10374168
    Abstract: The present application relates to heterospirobifluorene compounds, to a process for the preparation thereof, and to electronic devices, in particular organic electroluminescent devices, comprising the heterospirobifluorene derivatives.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: August 6, 2019
    Assignee: Merck Patent GmbH
    Inventors: Jochen Pfister, Frank Voges, Elvira Montenegro, Teresa Mujica-Fernaud
  • Compound with novel six-membered ring structure for use in organic electronic devices
    Patent number: 10374167
    Abstract: The present invention relates to novel compounds according to formula (I) having a six-membered ring structure substituted with electron donor, electron acceptor and sterically demanding groups. Said compound is suited for use in organic electronic devices, particularly in organic electroluminescent devices (OLEDs). Formula (I) wherein Q1 and Q2 are independently of each other selected from the group consisting of N, CRA, CRD, and CRS; Z1 and Z2 are independently of each other selected from the group consisting of N, CRA and CRD; RA is a group with ?M-effect; RD is a group with +M-effect; and RS is a sterically demanding group, with the provision that the compound of general formula (I) comprises at least one group CRA and at least one group CRD.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: August 6, 2019
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Amir Hossain Parham, Christof Pflumm, Anja Jatsch
  • Printed image
    Patent number: 10369831
    Abstract: The present invention relates to a printed image comprising flake-form effect pigments which has striking matt/gloss effects, to a process for the production of a printed image of this type, and to the use thereof, in particular in security printing.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: August 6, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Sylke Klein, Heidemarie Montag
  • Antigen-loaded chitosan nanoparticles for immunotherapy
    Patent number: 10369217
    Abstract: The present invention is directed to nanoparticles comprising chitosan and an antigen, whereby the chitosan has a degree of deacetylation of about 90% and a molecular weight from 5 kDa to 80 kDa, to microparticles containing such nanoparticles as well as to a process for preparation of such particles. The particles are usable for vaccination.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: August 6, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Andrea Hanefeld, Markus Weigandt, Michael Wolf, Percy Knolle, Matthias Schroeder, Regina Scherliess, Peter Walden, Andrea Diedrich, Hartwig Steckel, Renato Brito Baleeiro
  • Fullerene derivatives
    Patent number: 10374162
    Abstract: The invention relates to fullerene derivatives of formula I, to mixtures and formulations containing them, to the use of the fullerene derivatives, mixtures and formulations as organic semiconductors in, or for the preparation of electronic devices, especially organic photovoltaic (OPV) devices and organic photodetectors (OPD), and to electronic devices comprising, or being prepared from, these fullerene derivatives, mixtures or formulations.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: August 6, 2019
    Assignees: Merck Patent GmbH, Nano-C, Inc.
    Inventors: Nicolas Blouin, Stephane Berny, Edward A. Jackson, Henning Richter
  • Oxy-cyanoquinolinone PDE9 inhibitors
    Patent number: 10370337
    Abstract: The present invention is directed to oxycyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: August 6, 2019
    Assignee: Merck, Sharp & Dohme Corp.
    Inventors: Antonella Converso, Mildred L. Kaufman, Kevin Rodzinak
  • Aryl acylsulfonamides as BLT1 antagonists
    Patent number: 10370368
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B4 receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: August 6, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yongxin Han, Satyanarayana Tummanapalli, Phieng Siliphaivanh, Kerrie Spencer
  • Substituted oxepines
    Patent number: 10374170
    Abstract: The invention relates to materials, to electroluminescence devices comprising said materials and to the use thereof.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: August 6, 2019
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Arne Buesing, Philipp Stoessel, Anja Gerhard, Christof Pflumm, Thomas Eberle, Anja Jatsch, Jonas Valentin Kroeber, Lars Dobelmann-Mara
  • CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
    Publication number: 20190233463
    Abstract: The present invention relates to Cyclic Phosphate Substituted Nucleoside Compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein in A, B, R1, R2, R3, Q and V are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Compound, and methods of using the Cyclic Phosphate Substituted Nucleoside Compounds for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: June 20, 2017
    Publication date: August 1, 2019
    Applicants: MERCK SHARP & DOHME CORP., IDENIX PHARMACEUTICALS LLC
    Inventors: Stephane BOGEN, David DUKHAN, Guillaume BRANDT, Claire Pierra ROUVIERE, Cyril B. DOUSSON, Francois-Rene ALEXANDRE
  • ORGANIC SEMICONDUCTING COMPOUNDS
    Publication number: 20190237672
    Abstract: The invention relates to a blend containing an electron acceptor and an electron donor, the acceptor being an n-type semiconductor which is a small molecule that does not contain a fullerene moiety, the electron donor being a p-type semiconductor which is a conjugated polymer comprising donor and acceptor units in random sequence, to a formulation containing such a blend, to the use of the blend in organic electronic (OE) devices, especially organic photovoltaic (OPV) devices, perovskite-based solar cell (PSC) devices, organic photodetectors (OPD) and organic light emitting diodes (OLED), and to OE, OPV, PSC, OPD and OLED devices comprising the blend.
    Type: Application
    Filed: October 2, 2017
    Publication date: August 1, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: William MITCHELL, Nicolas BLOUIN
  • Process for Preparing Beta-Lactamase Inhibitor Hydroxylurea Intermediates
    Publication number: 20190233421
    Abstract: The present invention relates to processes for the preparation of N-protected (2S,5R)-6-hydroxy-7-oxo-N-piperidin-4-yl-1,6-diazabicyclo[3.2.1]octane-2-carboxamide intermediates. Such compounds have application in the preparation of beta-lactamase inhibitors such as 7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamides and esters, in particular, the beta lactamase inhibitor, (2S,5R)-7-oxo-N-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide. The present invention also encompasses intermediates useful in the disclosed processes and methods for their preparation.
    Type: Application
    Filed: September 14, 2017
    Publication date: August 1, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jianguo Yin, Zhijian Liu, Nobuyoshi Yasuda, Mark Weisel
  • HIGH DRUG LOAD POLYMERIC NANOPARTICLE FORMULATIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20190231705
    Abstract: Described herein are polymeric nanoparticles that comprise {[(1R,25)-1-({[(1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]-dioxadiazacyclo-nonadecino[11,12-b]quinoxalin-8-yl]carbonyl}amino)-2-vinylcylopropyl]carbonyl}(cyclopropylsulfonyl)azanide, (i.e., grazoprevir), or a pharmaceutically acceptable salt thereof, and methods of making and using such nanoparticles.
    Type: Application
    Filed: January 23, 2019
    Publication date: August 1, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Joseph Della Rocca, Angela M. Wagner, Wei Xu, W. Peter Wuelfing